BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19158414)

  • 1. Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.
    Jahnke K; Muldoon LL; Varallyay CG; Lewin SJ; Brown RD; Kraemer DF; Soussain C; Neuwelt EA
    Neuro Oncol; 2009 Oct; 11(5):503-13. PubMed ID: 19158414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
    Muldoon LL; Lewin SJ; Dósa E; Kraemer DF; Pagel MA; Doolittle ND; Neuwelt EA
    Clin Cancer Res; 2011 Apr; 17(8):2207-15. PubMed ID: 21385922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
    Miyake Y; Okoshi Y; Machino T; Chiba S
    Int J Hematol; 2010 Oct; 92(3):474-80. PubMed ID: 20820968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
    Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
    Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
    Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
    Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
    Santisteban M; Nieto Y; De la Cruz S; Aristu J; Zubieta JL; Fernández Hidalgo O
    Clin Transl Oncol; 2007 Jul; 9(7):465-7. PubMed ID: 17652061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma.
    Soussain C; Muldoon LL; Varallyay C; Jahnke K; DePaula L; Neuwelt EA
    Clin Cancer Res; 2007 Apr; 13(8):2504-11. PubMed ID: 17438111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Wong ET; Tishler R; Barron L; Wu JK
    Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors.
    Kubota T; Yamada K; Kizu O; Hirota T; Ito H; Ishihara K; Nishimura T
    J Magn Reson Imaging; 2005 Jun; 21(6):694-700. PubMed ID: 15906343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
    Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Shinbo Y; Hasegawa A; Onda K; Tanaka R
    Leuk Lymphoma; 2007 May; 48(5):1019-22. PubMed ID: 17487746
    [No Abstract]   [Full Text] [Related]  

  • 13. [
    Hovhannisyan N; Fillesoye F; Guillouet S; Ibazizene M; Toutain J; Gourand F; Valable S; Plancoulaine B; Barré L
    Theranostics; 2018; 8(16):4563-4573. PubMed ID: 30214639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
    Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.
    Tabouret E; Houillier C; Martin-Duverneuil N; Blonski M; Soussain C; Ghesquières H; Houot R; Larrieu D; Soubeyran P; Gressin R; Gyan E; Chinot O; Taillandier L; Choquet S; Alentorn A; Leclercq D; Omuro A; Tanguy ML; Hoang-Xuan K
    Neuro Oncol; 2017 Mar; 19(3):422-429. PubMed ID: 27994065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
    Yamanaka R
    Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.
    Pels H; Schulz H; Manzke O; Hom E; Thall A; Engert A
    J Neurooncol; 2002 Sep; 59(3):213-6. PubMed ID: 12241117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption.
    Macnealy MW; Newton HB; McGregor JM; Bell SD; Ray Chaudhury A; Slone HW; Bourekas EC
    J Neurooncol; 2008 Dec; 90(3):329-33. PubMed ID: 18758913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
    Pels H; Schulz H; Schlegel U; Engert A
    Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.